| Document |
Document Title |
|
JP6254075B2 |
The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the tr...
|
|
JP2017537960A |
The present invention provides a method for regulating the activity of the farnesoid X receptor (FXR) using a compound of formula (I) or (II). In particular, the present invention provides the use of compounds of formula (I) or (II) for ...
|
|
JP2017206440A |
To provide a novel bactericide for agricultural and horticultural use, a novel pest control agent, and a novel insecticidal or miticide.This invention relates to a compound represented by formula (I-1), or a tautomer thereof or salt. Thi...
|
|
JP2017206437A |
To provide a new compound having fibroblast growth factor receptor (FGFR) inhibitory action, and a pharmaceutical composition containing the same.The present invention provides a compound represented by formula (I) or pharmaceutically ac...
|
|
JP6229042B2 |
The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as ...
|
|
JP6224004B2 |
An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present inventio...
|
|
JP6223563B2 |
Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemi...
|
|
JP6221189B2 |
|
|
JP6224256B2 |
The invention generally provides processes for the preparation of radioiodinated 3-fluoropropyl-nor-β-CIT. In particular, the process uses an arylsilane intermediate, thus avoiding the use of hexamethylditin, and reducing the number of ...
|
|
JP6215212B2 |
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including,e.g., in the treatment or prevention of cancer, a ne...
|
|
JP2017528464A |
The present disclosure is based on formula (I) :. [Chemical 1](In the formula, R1, B, X, and Z are defined herein) as well as pharmaceutically acceptable salts and solvates thereof. The present disclosure also relates to the use of compo...
|
|
JP6204476B2 |
This invention relates to compounds (Formula (1)) that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing...
|
|
JP6204985B2 |
The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
|
|
JP6197203B2 |
A 9-azabicyclo[3.3.1]nonan-3-one derivative is reacted with a hydrogen in the presence of a catalyst composed of a ruthenium complex to obtain, at a low cost, an endo-9-azabicyclo[3.3.1]nonan-3-ol derivative useful as a production interm...
|
|
JP6192016B2 |
The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are...
|
|
JP6189434B2 |
The present invention provides compounds of Formula (I) for the treatment of cancer, rheumatoid arthritis and other diseases.
|
|
JP6188028B2 |
|
|
JP6180432B2 |
The present invention relates to certain amide derivatives that have the ability to inhibit 11-beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD-1) and which are therefore useful in the treatment of certain disorders that can be prev...
|
|
JP6173453B2 |
The disclosure relates to Cyclic Urea- or Lactam-Substituted Quinoxaline-Type Piperidine Compounds of Formula (I): and pharmaceutically acceptable derivatives thereof wherein R1, R2, Qa, Y1, Z, A, B, Qx, E, G, J, M, U, W, and a are as de...
|
|
JP2017518348A |
The present invention provides substituted indazole compounds of formula (I) and pharmaceutically acceptable salts thereof, as well as their use for inhibiting IRAK4 and / or for treating diseases or disorders induced by IRAK4. To do.
|
|
JP6158939B2 |
A method for stabilization of micronized or milled solvates of tiotropium bromide, in which the solvates are deposited in a saturated atmosphere of the adequate solvent for the time period sufficient for recovery of the original amount o...
|
|
JP6155270B2 |
Disclosed are compounds of formula (I) which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which Bcl-xL proteins are expressed, eg cancer. X is heter...
|
|
JP6148402B2 |
This invention provides a novel disubstituted 1,2,4-triazine compound or a pharmaceutically acceptable salt thereof, which has an aldosterone synthetase inhibitory activity and is useful for preventing and/or treating various diseases or...
|
|
JP6120861B2 |
Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful ...
|
|
JP6118826B2 |
The present invention relates to a novel process for the preparation of tiotropium bromide there is provided a process for preparing tiotropium bromide comprising (i) reacting scopine oxalate with diethylamine in an inert solvent to form...
|
|
JP6110516B2 |
The present disclosure provides substituted pyrimidine carboxamides of Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein A 1 , X, A 2 , W 1 , W 2 , W 3 , E, Z, and R 4 are defined as set forth in the spec...
|
|
JP2017057206A |
To provide a method of treating pain of mammalian.There is provided a novel compound having the general formula (I), where variable R, subscript n, ring A, X, L, subscript m, X, B, R, R, R, R, Rand Rhave meanings described in the specifi...
|
|
JP6099753B2 |
These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of acyl CoA diacyl glycerol acyltransferase 1 (DGAT1).
|
|
JP6099051B2 |
The present invention is related to a compound represented by formula (I), wherein X 1 , X 2 , X3, X4, X5, R 5 , R 6 , R 7 , R 8 , n, p, q, ring A and ring B are as described in the specification, or a pharmaceutically acceptable salt th...
|
|
JPWO2015046193A1 |
In the present invention, the formula (I):(In the formula, R1Is a hydrogen atom, a substituted or unsubstituted alkyl, a substituted or unsubstituted aromatic carbocyclic group, etc .; X is -N (R)2)-, -O- or -S-; Y is = C (R)3)-Or = N-; ...
|
|
JP6088491B2 |
A medicament for treating diseases associated with cholinergic properties in the central nervous system (CNS) and/or peripheral nervous system (PNS), diseases associated with smooth muscle contraction, endocrine disorders, neurodegenerat...
|
|
JP6080051B2 |
Compounds of formula(I) act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive and inflammatory diseases.
|
|
JP2017001954A |
To provide a bactericidal agent for agriculture exhibiting high controlling effect on wide range of plant pathogens.There are provided a compound represented by the formula (I), where each symbol has the same meaning in the specification...
|
|
JP6047168B2 |
which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
|
|
JP6045320B2 |
A continuous process for the alkylation of tertiary amines and, in particular, to a continuous process for the quaternization of cyclic tertiary amines useful for the preparation of cyclic quaternary ammonium salts with high purity is de...
|
|
JP6038792B2 |
The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An embodiment of the invention is the provision of a compound of Formula IIIA.
|
|
JP2016537303A |
The present invention relates to a substitution phenylalanine derivative and a manufacturing method for the same, and relates also to use of the above-mentioned derivative for manufacturing the medicine for treating and/or preventing the...
|
|
JP6034412B2 |
Disclosed is a process for the preparation of the compound of formula (471)
|
|
JP6025066B2 |
The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointesti...
|
|
JP2016534127A |
The compound of formula I(The inside of a formula, A, Q, R)1And R2as being defined as Is the claim 1 -- it is -- it is provided. The present invention relates to these directions for use for exterminating and controlling the intermediate...
|
|
JP6007189B2 |
Compounds of Formula (I) are used for the treatment of inflammation and autoimmune disorders.
|
|
JP5980236B2 |
The present invention provides a diaminopyrimidine derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same, and a use thereof. The diaminopyrimidine deri...
|
|
JP5969004B2 |
A compound having the following general formula (I): wherein: X is a nitrogen atom and Y is a carbon atom; or X is a carbon atom and Y is a nitrogen atom; the Ar group is an aryl or heteroaryl group; and the RN and RN' groups, together w...
|
|
JP2016138122A |
To provide a low molecular weight compound being an antagonist of chemokine receptor function.The method comprises administering to a subject an effective amount of a compound represented by formulas (I) and (II) or physiologically accep...
|
|
JP2016520536A |
the present invention -- Neoniko chino -- an id -- the insect (especially) which is resistance to an insecticideA control method of an insect using the compound (the inside of a formula, A, R1, and R2 are as defining above) of formula I ...
|
|
JP5952829B2 |
The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J1, J2, R1, R2, R3, R22, Ra, Rb, Rc, Rd, X, Y, b, n, and q are as defined herein. The invention als...
|
|
JP5936669B2 |
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: ...
|
|
JP2016517432A |
The compound of formulas I' and I useful as the irritating agent of sGC, especially a heme dependence irritating agent of NO non-dependence is indicated. These compounds are useful also in order to treat, prevent or manage various obstac...
|
|
JP2016516710A |
Compound of formula (Ia) [R2, R12, R16, J, Q, X, Y and Z are as defined in the specification. ] And pharmaceutically acceptable salts thereof are disclosed. The compound can be used as a drug in the treatment of diseases such as cancer. ...
|
|
JP2016515551A |
the present invention -- Neoniko chino -- an id -- a useful arthropod is not affected although how to control the insect (an insect which it is eye a half-wing especially and is called especially a plant louse and Whitefly ) which is tol...
|
